---
title: "CSTL: Q2 2026 revenues up 20% YoY to $103.5M, driven by TissueCypher growth; net loss $2.1M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294410258.md"
description: "Q2 2026 revenues rose 20% year-over-year to $103.5M, led by strong TissueCypher growth, while dermatologic test revenues declined due to Medicare coverage loss for DecisionDx-SCC. Gross margin remained strong at 74.9%, but net loss was $2.1M as operating expenses increased. Liquidity remains solid, with $62.1M in cash and $204.7M in securities.Original document: Castle Biosciences, Inc. [CSTL] SEC 10-Q Quarterly Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T20:17:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294410258.md)
  - [en](https://longbridge.com/en/news/294410258.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294410258.md)
generator: "portal-rs"
---

# CSTL: Q2 2026 revenues up 20% YoY to $103.5M, driven by TissueCypher growth; net loss $2.1M

Q2 2026 revenues rose 20% year-over-year to $103.5M, led by strong TissueCypher growth, while dermatologic test revenues declined due to Medicare coverage loss for DecisionDx-SCC. Gross margin remained strong at 74.9%, but net loss was $2.1M as operating expenses increased. Liquidity remains solid, with $62.1M in cash and $204.7M in securities.

Original document: Castle Biosciences, Inc. \[CSTL\] SEC 10-Q Quarterly Report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CSTL.US](https://longbridge.com/en/quote/CSTL.US.md)

## Related News & Research

- [238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC](https://longbridge.com/en/news/296578673.md)
- [Castle Biosciences begins dual listing on Nasdaq Texas under CSTL](https://longbridge.com/en/news/296094680.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**